The FDA on Wednesday approved the first gene therapy for a chronic condition — bluebird bio's new Zynteglo (beti-cel) as a potentially curative treatment for those with transfusion-dependent thalassemia. The thumbs up from the FDA follows a unanimous adcomm v…